Parang, Keykavous Assistant Professor  Pharm. D., 1989  Ph.D., University of Alberta ,1997 Postdoctoral fellow, Department of Chemistry, University of Alberta, 1997  Postdoctoral Fellow, Department  of Bioorganic Chemistry, Rockefeller University Postdoctoral Fellow, Department of Pharmacology and Molecular Sciences, School of Medicine Johns Hopkins University School of Medicine, 2000  Phone:    (401) 874-4471  E-mail: kparang@uri.edu Department of Biomedical Sciences

Research Interests

Our research is appropriately described as "the application of synthetic organic chemistry to problems in biology". We synthesize peptide-based molecules not available in nature and develop new methods for this purpose when it is required. Synthetic targets are often enzymes like tyrosine kinases. 

Specific areas currently under investigation include:

• Designing protein tyrosine kinase inhibitors. 
• Novel strategies in the solid-phase synthesis of phosphopeptides and thiophosphopeptides and screening biologically active compounds. 

• Novel approaches in designing bifunctional antiinfective agents. Currently our focus is to design prodrugs of antifungal agents and HIV microbicides.

• New methods for solid-phase synthesis.

Publications:

 2. Nam N. H., Lee S., Ye G., Sun G., Parang K. ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases. Bioorg. Med. Chem. (2004) 12, 5753-5766.

3. Nam N. H., Sardari S., Selecky M., Parang K. Carboxylic acids and phosphate ester derivatives of fluconazole: synthesis and antifungal activities. Bioorg. Med. Chem. (2004) 12, 6255-6269

4. Schmidt B., Jiricek J., Titz A., Ye G., Parang K. Copper dipicolinates as peptidomimetic ligands for the Src SH2 domain. Bioorg. Med. Chem. Lett. (2004) 14, 4203-4206.

5. Nam N. H., Ye G., Sun G., Parang K. Conformationally Constrained Tetrapeptide Analogues of pYEEI as Src-SH2 Domain Inhibitors. J. Med. Chem. (2004) 47, 3131-3141.

6. Carballeira N. M., Ortiz D., Parang K., Sardari. S. Total synthesis and in vitro antifungal activity of 2-methoxytetradecanoic acid. Archiv der Pharmazie - Pharmaceutical and Medicinal Chemistry (2004) 337, 152-155.

7. Force T.,  Kuida K., Namchuk M.,  Parang K., Kyriakis J. M.  Inhibitors of Protein Kinase Signaling Pathways.    Circulation (2004) 109, 1196-1205.

8.  Nam N. H., Pitts R., Sun G., Sardari S., Tiemo A., Xie M., Yan B., Parang K. Design of Tetrapeptide Ligands as Inhibitors of the Src SH2 Domain. Bioorgan. Med. Chem. (2004) 12, 779-787..

9.  Lee S., LinX., Nam N. H., Parang K., Sun G. Determination of the Substrate-Docking Site of Protein Tyrosine Kinase Csk. Proc. Nat. Acad. Sci. (2003) 100, 14707-14712.

10. Nam N. H., Sardari S., Parang K. Reactions of solid supported reagents and solid supports with alcohols and phenols through their hydroxyl functional group, J. Comb. Chem., 5, 479-546, 2003.

11. Sardari S., Pourmorad F., Tiemo A., Nam H., Parang K., Protein kinases and their modulation in the central nervous system, Current Medicinal Chemistry-CNS, 3, 341-364, 2003.

12. Parang K., Editor, Anti-HIV design, Current Pharmaceutical Design, 9, 71 pp., 2003.

13. Nam N. H., Parang K. Current Drug Targets for Anticancer Drug Discovery, Current Drug Targets,  4, 159-179, 2003.

14. Parang K., Kohn J. A., Saldahna A., Cole P. A. Development of photo-crosslinking reagents for protein kinase-substrate interactions, Febs Letters, 520, 156-160, 2002.

15. Parang K., Polymer-supported reagents for methylphosphorylation and phosphorylation of Carbohydrates, Bioorganic Med. Chem. Lett., 12, 1863-1866, 2002.

16. Parang K., Cole P. A., Bisubstrate inhibitors of protein kinases, Pharmacology and Therapeutics, 93, 145-157, 2002.

17. Parang K., Anti-HIV design, Preface, Current Pharmaceutical Design, 8, U4-U4, 2002.

18. Cole. P. A., Parang, K., Abloogu A., Kohnaski R. A., Courtney A., Bisubstrate Inhibitors of kinases, U. S. Patent, 2002, 0031820 A1.

19. Courtney A., Cole, Philip A., Parang K., Ablooglu A., Kohanski R., Bisubstrate inhibitors of kinases. PCT Int. Appl. 2001, 39 pp. WO 0170770  A2 20010927 AN 2001:713377.

20. Parang K., Till J. H., Ablooglu A. J., Kohanski R. A., Hubbard S. R., Cole P. A., Mechanism-based design of a protein kinase inhibitor, Nature Structural Biology, 8, 37-41, 2001.

21. Parang K., Fournier E. J.-L., Hindsgaul O., A solid phase reagent for the capture phosphorylation of carbohydrate and nucleosides, Organic Letters, 3, 307-309, 2001.

22. Ablooglu A. J., Till J. K., Kim K., Parang K., Cole P. A., Hubbard S. R., Kohanski R. A., Probing the catalytic mechanism of the insulin receptor kinase with a tetrafluorotyrosine-containing peptide substrate, J. Biol. Chem., 275, 30394-30398, 2000.

23. Parang K.*, Kim K.*, Lau O. D., Cole P. A., Tyrosine analogs as alternative substrates for protein tyrosine kinase Csk: insights into substrate selectivity and catalytic mechanism, Bioorg. Med. Chem., (* Both authors have contributed equally), 8, 1263-1268, 2000.

24. Parang K., Wiebe L. I., Knaus E. E., Novel approaches in designing prodrugs of AZT, Current Medicinal Chemistry, 7, 995-1039, 2000.

25. Parang K., Wiebe L. I., Knaus E. E., Huang J. S., Tyrrell D. L., In vitro anti-hepatitis B virus activities of 5’-O-myristoyl analogue derivatives of 3’-fluoro-2’,3’-dideoxythymidine (FLT) and 3’-azido-2’,3’-dideoxythymidine (AZT), J. Pharm. Pharmaceut. Sci. (www.ualberta.ca/~csps), 1, 107-113, 1998.

26. Parang K., Knaus E. E., Wiebe L. I., Synthesis, in vitro anti-HIV activity, and biological stability of 5’-O-myristoyl analogue derivatives of 3’-fluoro-2’,3’-dideoxythymidine (FLT) as potential prodrugs of FLT, Nucleosides & Nucleotides, 17, 987-1008, 1998.

27. Parang K., Wiebe L. I., Knaus E. E., In vivo pharmacokinetic parameters, liver and brain uptake of (±)-3’-azido-2’,3’-dideoxy-5’-O-(2-bromomyristoyl)thymidine as potential prodrug of 3’-azido-3’-deoxythymidine, J. Pharm. Pharmacol., 50, 989-996, 1998.

28. Parang K., Knaus E. E., Wiebe L. I., Synthesis, in vitro anti-HIV structure-activity relationships and stability of 5’-O-myristoyl analogue derivatives of 3’-azido-2’,3’-dideoxythymidine as potential prodrugs of 3’-azido-2’,3’-dideoxythymidine (AZT), Antiviral. Chem. Chemother., 9, 311-323, 1998.

29. Parang, K., Wiebe, L. I., Knaus, E. E. Syntheses and biological evaluation of 5’-O-myristoyl derivatives of thymidine against human immunodeficiency virus (HIV-1). Antiviral. Chem. Chemother., 8, 417-427, 1997.

30.  Parang K., Wiebe L. I., Knaus E. E., Huang J. S., Tyrrell D. L., Csizmadia F., In vitro antiviral activities of myristic acid analogs against human immunodeficiency and hepatitis viruses, Antiviral Research, 34, 75-90, 1997.

31.  Parang K., Knaus E. E., Wiebe L. I., Sardari S., Daneshtalab M., Csizmadia F., Synthesis. and antifungal activities of myristic acid analogs, Arch. Pharm.-Pharm. Med. Chem., 329, 475-482, 1996.

32. Sharifan A., Parang K., Zorrieh-Amirian H., Nazarinia M., Shafiee A., Synthesis of 1-substituted 1,2,4-triazoles, imidazoles and benzimidazoles, J. Heter. Chem., 31, 1421-1423, 1994.

33. Shafiee A. Pirouzzadeh B., Ghasemian F., Parang K., Synthesis of 2-acetyl-1-methyl -5-nitroimidazole, J. Heter. Chem., 29, 1021-1023, 1992.

34. Shafiee A., Parang K., Khazen M., Ghasemian F., Synthesis of substituted 2-(1-methyl-5- nitro-2-imidazolyl)quinolines, J. Heter. Chem., 29, 1859-1861, 1992.
 
 
 
 
 
 
 
 
 
 
 

Back to Faculty Page